Pheon Therapeutics appoints CMO

UK antibody-drug conjugate (ADC) company Pheon Therapeutics today announced the appointment of Dr Arvin Yang as chief medical officer.

Dr Yang joins Pheon with over a decade of experience in leading therapeutic oncology products through early-stage clinical development, and late-stage global registration trials at both Bristol Myers Squibb (NYSE: BMY) and Mersana Therapeutics.

At Mersana Therapeutics, Dr Yang oversaw the clinical development of multiple novel assets in both early and late-stage global development. Prior to his work at Mersana, Dr Yang spent over a decade at Bristol Myers Squibb, in a variety of leadership roles, making contributions that spanned all stages of the development process, from discovery through late-stage clinical trials and approvals. His work included generating clinical development plans and driving the approvals of nivolumab, ipilimumab, fedratinib, and luspatercept.